Method for post-operational treatment of donor's wounds

FIELD: medicine, surgery.

SUBSTANCE: one should apply a polycompositional film onto donor's wounds after autodermoplasty performed. This film contains the following components in weight proportions: chitosan 78.3-89.4; polyvinyl alcohol 9.8-19.8; antibiotic of aminoglycoside group 0.5-2.0; anesthetic 0.1-0.2. It is perforated at tension coefficient being 1:4. The innovation enables to decrease wound's traumatization, improves prophylaxis of suppuration and increases cosmetic effect even at a single application of the film suggested.

EFFECT: higher efficiency of therapy.

2 ex


The present invention relates to medicine, namely to surgery, and can be used in surgical wards and in the outpatient network.

The treatment of burn wounds remain. Used for these purposes, new drugs and tools must meet the following requirements: to isolate the wound from infection; and to protect it from dehydration, reduce the heat, have some antibacterial properties, contribute to early epithelization. In recent time there are many samples of wound coverings, differing in chemical composition. However, so far there is no universal drug (Bairamov, Aoarashi, Weglarski "Burns" guide, St. Petersburg, spec lit, 2000).

One of the new drugs used in the burn center hospital №18 of Ufa, is a coating based on PVA and chitosan in combination with an antibacterial agent. One of the indications generated bipartite is to protect the donor site after autodermoplastiki.

Contraindications to the use of these biocrete not found.

Known coating for the treatment of wounds donor places with the use of a perforated film of polyvinyl alcohol. This film under the title "miniplan" produced Okhta scientific about svojstvennym Association Plasmapool" (Nizhny Novgorod research Institute of traumatology and orthopedics, Sepahaua Surgery of burns in children, 1997, P.118-121).

The method of treatment is simple. After cutting the skin graft donor wound impose a gauze pad, then it's removed, respectivey perforated foil, cover with 2-3 layers of gauze and secured with a bandage. The film leave until complete healing. After healing of the wound film is gradually falling behind and it is removed. The healing time of wounds from 6 to 12 days after the operation.

Unlike the proposed method:

Time epithelialization 6-12 days.

Film single pack consists of degradiruemosti PVA, after healing of the wound occurs the necessity of removing the film.

Not antibacterial, anesthetic properties.

Performs only the function of mechanical protection, protecting the wound from external mechanical influences.

Film bioinert, enzymatic not are degraded, decomposed due to the swelling and mechanical damage, which is a long process.

Not marked reuse epithelizing donor places as the donor site.

Closest to the claimed is a method of treatment of donor wounds, which use complex film coating, developed at the Department of conservation tissues NIETO, which is a membrane consisting of layers of polysaccharides and collagen, and pregnenolone fine DCM (demineralized bone matrix). The polysaccharide layer contains antibacterial (application No. 98102038 from 28.01.98).

The film is fixed on the wound without adhesive means and allows visual monitoring of the condition of the wound. Developed coating can reduce the healing time of donor wounds for 4-7 days.

In a functional purpose to the disadvantage of the coating is that the coating can remain on the wound surface only a few days. When single use CPR is not enough, it requires the use of two or more times, thus the necessary condition is the removal and replacement of the film coating.

Layer-by-layer (membrane) structure checkpoint, including collagen, prevents the full enzymatic biodegradation of the coating on the wound surface in a time comparable with the period of epithelialization, the consequence of which is the need to replace the transmission. The experience of the applicant shows that when using pure collagen even in the form of fibrous material not observed any significant birthrate material 1-2 weeks of being on the wound surface (proceedings of the 7th all - Russian scientific-practical conference on the problems of thermal lesions. Chelyabinsk, 1999).

The task of the claimed invention is an improvement of the method cured the I donor wounds after surgery loose skin autoplasty.

The technical result when using the reduction of treatment time, improve functional results.

The proposed method is implemented as follows.

After running autodermoplastiki on the surface of donor wounds once impose perforated 1:4 film containing chitosan, polyvinyl alcohol, antibiotic aminoglycoside number of gentamicin and anesthetic, with the following ratio of components, in mass proportions: chitosan 78,3-89,4; polyvinyl alcohol 9,8-19,8; antibiotic 0.5 to 2.0; anesthetic 0.1 to 0.2. The film is fixed with a bandage. The next day the gauze bandage is removed, the film leave until complete wound healing. Experimentally found the ratio of the polymer components to achieve the required level of strength and elasticity of the film, providing the possibility of mechanical punching, sufficient for practical use, using standard equipment and safety forms even perforated film on the surface of the wound in the early postoperative period.

This represents a major problem when using pure chitosan, quickly swelling to wet the surface and losing strength. The film does not prevent the desiccation of the wound surface that does not retain moisture, enough gaspron zaema to ensure flowing of reparative processes, requiring oxygen. The ratio of the components, in which the continuous phase is birthdaaay polyaminoacid, and perforated structure ensure the complete destruction of the coating to the end of the regeneration phase of the wound healing process, thereby reducing trauma to the wound, namely germ layer. Due to the rapid healing of the donor wounds reduced time to re-fence the skin.

The reduction in the content of PVA against the proposed leads to an undesirable reduction of the period of existence of the integral coating on the wound, and the increase of its content leads to the fact that after epithelialization of the wound surface are fragments of the coating that must be removed mechanically.

Being transparent and sufficiently elastic, it allows visual observation of the condition of the wound and well-modeled on the skin surface.

Marked good cosmetic effect.

The main tasks to be addressed the proposed method are:

- prevention of infection of the wounds, stimulation of reparative processes;

a good cosmetic effect;

- ability to improve the timeliness of donor sites for re-sampling of the skin.

The associated analysis of the prototype shows that the inventive method differs from the known fact that Les is possible donor RAS use single use perforated film based on a mixture of chitosan and synthetic polymer polyvinyl alcohol. This allows to make a conclusion on the conformity of the proposed solutions to the criterion "novelty". The film has biocidal properties, performs mechanical protection, stimulates reparative processes. The possibility of introducing anesthetic in the composition of the film provides a local anesthetic to numb the wound surface. Time epithelialization of donor wounds - from 4 to 7 days.

From the literature we have found the use of film to protect the donor wounds of this composition. Experimentally chosen percentage of components.

The proposed method for the treatment of donor wounds has features that distinguish it not only from the way the prototype, but also on other technical solutions. The authors experimentally demonstrated that a single application of films containing chitosan and polyvinyl alcohol, perforated 1:4, leads to a considerable reduction of terms of epithelialization of the wound and a good remote results, thus, the present invention meets the criterion of "inventive step".

The method was tested in the burn Department of the city clinical hospital №18 of Ufa, in the group of ten patients with extensive deep burns of different localization. The control process carried out on the basis of a number of clinical criteria: period of epithelialization, bacteriological research, these cytologica is to change the Russian Academy of Sciences, but also consider the long-term results.

Example No. 1. Case history No. 20.

Patient Yusupov was hospitalized in the burn unit with 08.01.04 on 09.02.04,

The final diagnosis clinical: Burn 3 - B Art. trunk, perineum, lower limb 12%. Burn recovery.

History: trauma 30.12.03. household hot water. Performed in the outpatient area of the dressing to the desired result has not led, transferred to the RTC. Treatment in the postoperative period by the proposed method. The results of the treatment was evaluated by clinical effectiveness - the case of epithelialization, cytological changes, RAS, bacteriological monitoring of the wound.

The purpose of comparative study of the method, the donor site of the right lower limb were deposited film, and the wounds on the left limb was carried out in the traditional way.

In the burn wound treated under the films, there is a change in the cellular composition of tissues compared with wounds treated with bandages. Cytological study of wound surface covered by a film, revealed a decrease in the number of neutrophils and higher, compared with the control plots, the number of Poliplast and macrophages, which indicates that during the process of regenerative type. Bacteriological monitoring of the wound is obnarujeno quantitative reduction of microflora compared to control plots. With a good performance of the cytograms, the microbial landscape of wounds received good results - complete epithelialization of donor wounds under film for 4-6 days, in the control case epithelialization 10 - day.

Data bacteriological tests:

21.01.04. smear with wounds after ADP-stroke with RAS under the film - St. epidemidis 1st degree control - St. Aureus 1st degree

23.01.04. smear with RAS under the film - Acineto lwoffii 1st degree control - St. Acineto lwoffii 1st degree, St. Aureus 1st degree

25.01.04. smear with RAS under the film - growth of bacteria not detected control - Acineto lwoffii 1st degree, St. Aureus 1st degree.

The results of the cytograms

3 - the day after the ADP-control: macrophages 1-0-1 in the field of view

experiment: tissue macrophages 3-4-3 in the field of view, vacuolization of the cytoplasm

5 - the day after the ADP-control: macrophages 2-1-2 in the field of view

fibroblasts 1-0-1

plasma cells 2-1-0

experiment: tissue macrophages 4-3-6

in the field of view fibroblasts 3-2-1

plasma cells 2-1-1

elastic fibers +

For dynamic monitoring stations maintained by the film, through the month stated a good cosmetic effect. Unchecked growth of scar tissue, unlike other areas maintained the traditional method.

In this case, there were signs of growth in young scar tissue, itching, discomfort.

Case history No. 47.

Bo is Inoi Erastov,, 49 L. were treated in the Department with 19.01.04.-16.12.04.

Diagnosis clinical: Granulating wound body 10%. Burn recovery.

Treatment on the selected scheme - after ADP single overlay plates on donor sites.

04.02.04. - ADP 250 cm2

In the postoperative period for cytological examination was taken brushstrokes - prints under the films and under the bandages. On the 4th day after surgery, after treatment under the plates microflora was no longer determined by comparison with the control.

Data bacteriological tests:

06.02.04. smear with RAS under the film - St. epidemidis 1st degree control - St. Aureus 1st degree, Pseudomonas aeruginosa 1st degree.

08.02.04. smear under the plate the growth of bacteria not detected, the control - St. saprophyticus 1st degree, St. Aureus 1st degree.

The results of the cytograms.

After autodermoplastiki over 3 days:

smear under the plate - tissue macrophages 3-4-3 in the field of view

plasmablast 1-1-2, sometimes up to 11 in the field of view

control macrophages 1-3-1 in the field of view

neutrophils in large quantities

fibroblasts 1-0-1 in the field of view

5 - day

smear under the plate - collagen fibers +

tissue macrophages with varying degrees of maturity cytoplasm

8-6-8 in the field of view

neutrophils isolated in a field of view

fibroblasts 2-1-1 in the field of view

collagen fibers +

PLA is automatic cell 2-1-1

control macrophages 3-4-2 in the field of view

neutrophils 20-23-21 in the field of view

fibroblasts 1-0-1 in the field of view.

Thus, given the above, there is reason to believe that the proposed treatment of the donor wound is more effective and preferable compared to the other for several reasons:

first, it reduces the number of dressings, trauma wounds, rapid epithelialization, prevention of suppuration, the ability to reuse epithelizing donor places as donor sites when you conduct autodermoplastiki, anesthetic effect, good cosmetic result;

secondly, the method is simple to use, economical, can be used in the outpatient network.

Thus, the present invention meets the criterion of "industrial application".

Treatment of donor wounds, including the application of precompositional film containing polysaccharide and an antimicrobial substance on donor wounds after autodermoplastiki, characterized in that once lay film, which further comprises polyvinyl alcohol and anesthetic, and as a polysaccharide and antibacterial substances it contains, respectively, the chitosan and the aminoglycoside antibiotic series, such as gentamicin, p is hairouna with coefficienta stretching 1:4, when the following ratio of components, parts by weight:

Polyvinyl alcohol : 9,8-19,8
Antibiotic aminoglycoside number0,5-2,0


Same patents:

FIELD: medicine.

SUBSTANCE: the present innovation deals with application of pleuromutilin derivatives, that is valnemulin and thiamulin, for transdermal treatment of bacterial diseases, in particular those induced by Dichelobacter nodosus, Fusobacterium necrophorum, Bacteriodes nodosus and Bacteriodes melamnogenicus, for manufacturing medicinal preparation or as an active ingredient of medicinal preparation of the same indication and corresponding method for transdermal treatment of diseases, for example foot rot. It has been detected the capacity of antibiotics to penetrate skin and enter either plasma or blood at concentrations being efficient against systemic bacterial infections, so, medicinal preparation could be designed in the form of ointment, cream, solution, shampoo, powder and spray.

EFFECT: higher efficiency of application.

9 cl, 1 tbl

FIELD: biotechnology, immunology.

SUBSTANCE: invention proposes preparation that comprises the immunoelectrophoretically pure secretory immunoglobulin A isolated from whey milk and/or colostrum of immunized ungulate animals and pharmaceutically acceptable vehicles. The base preparation (substance) comprises 6-12% of secretory immunoglobulin A at pH 4-8, an anti-complementary activity at least 10 mg of protein, not activating 2 CH50, protects in >70% against corresponding infections (in infection macroorganism in doses ≥10 ID50), shows areactogenic property in intravenous administration, can comprise stabilizing additives in the total concentration 4%, not above. The preparation possesses high purity, low anti-complementary activity, stable in storage, useful for oral, parenteral and topical using and possesses therapeutic activity with respect to microorganisms and viruses against which humans and animals immunization have been carried out. Invention can be used in treatment and prophylaxis of immunodeficiency states, bacterial and viral infections in humans and animals.

EFFECT: valuable medicinal and veterinary properties of preparation.

9 cl, 1 tbl, 10 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to novel heterocyclic compounds comprising 2-aminopyridin-3-sulfonic fragment of the general formula (1) or their pharmaceutically acceptable salts, N-oxides or hydrates possessing properties of antagonists of glutamate-induced calcium ions transport, in particular, neuroprotective effect. Also, invention relates to the focused library for the search of biologically active leader-compounds comprising at least one heterocyclic compound of the general formula (1) and to pharmaceutical composition if form of tablets, capsules or injections placed into pharmaceutically acceptable package containing compounds of invention as an active substance. In compound of the general formula (1) R1 represents hydrogen atom; R2 represents chlorine atom, optionally substituted hydroxyl group, optionally substituted amino-group, optionally substituted azaheterocyclyl; or R1 and R2 in common with nitrogen and sulfur atoms to which they are bound form optionally substituted and optionally condensed with other cycles 1,1-dioxo-4H-pyrido[2,3-e][1,2,4]thiadiazine or optionally substituted and optionally condensed with other cycles 5,5-dioxo-5,6,7,9-tetrahydro-5-thia-1,6,9-triazabenzocyclohepten-8-one. Also, invention discloses methods for preparing different compounds of the general formula (1).

EFFECT: improved preparing methods, valuable medicinal properties of compounds.

10 cl, 4 sch, 4 tbl, 9 ex

FIELD: organic chemistry, biochemistry, pharmacy.

SUBSTANCE: invention relates to new heterocyclylsulfonyl alkylcarboxylic acids and their derivatives of the general formula (1): or their pharmaceutically acceptable salts, N-oxides or hydrates possessing the inhibitory effect on kinase activity and to the focused library for search of active leader-compounds comprising at least abovementioned compound. In the general formula 91) W represents optionally substituted heterocyclic radical, among them: pyrrole-3-yl, thiophene-2-yl, isooxazole-4-yl, pyrazole-4-yl, imidazole-4-yl, pyridine-3-yl, 1H-2,4-dioxopyrimidine-5-yl, 2,3-dihydro-1H-indole-5-yl, 2,3-dihydro-1H-indole-7-yl, 1,3-dihydro-2-oxoindole-5-yl, 2,3-dioxo-1H-indole-5-yl, 2-oxo-3H-benzoxazole-6-yl, benzothiazole-6-yl, 1H-benzimidazole-5-yl, benzo[1,2,5]oxadiazole-4-yl, benzo[1,2,5]thiadiazole-4-yl, 1,2,3,4-tetrahydroquinoline-6-yl, 3,4-dihydro-2-oxo-1H-quinoline-6-yl, quinoline-8-yl, 1,4-dihydro-2,3-dioxoquinoxaline-6-yl, 3-oxo-4H-benzo[1,4]oxazine-7-yl, 3-oxo-4H-benzo[1,4]thiazine-7-yl, 2,4-dioxo-1H-quinazoline-6-yl, 2,4-dioxo-1,5-dihydrobenzo[b][1,4]diazepine-7-yl or 2,5-dioxo-3,4-dihydrobenzo[b][1,4]diazepine-7-yl; Y represents optionally substituted methylene group; R1 represents chlorine atom, optionally substituted hydroxyl group, optionally substituted amino-group, optionally substituted azaheterocyclyl; n = 1, 2 or 3; or Yn represents carbon atom of optionally substituted (C3-C7)-cycloalkyl or optionally substituted (C4-C7)-heterocyclyl. Also, invention relates to a pharmaceutical composition in form of tablets, capsules or injections placed into pharmaceutically acceptable package.

EFFECT: valuable properties of compounds.

5 cl, 3 sch, 5 tbl, 6 ex

FIELD: organic chemistry, chemical technology, antibiotics.

SUBSTANCE: derivative of 9-deoxo-9a-aza-9a-homoerythromycin A of the formula (3) wherein R4 represents hydroxyl protecting group is prepared by protection of 2'-hydroxy-group of compound of the formula (5) to form compound of the formula (4)

and by oxidation of C-4''-hydroxy-group of compound of the formula (4) that is carried out by addition of dimethylsulfoxide to solution containing compound of the formula (4) and a solvent followed by cooling the mixture up to about -70°C, activation of dimethylsulfoxide in situ and defoaming the reaction mixture. Compound of the formula (4) is converted to the oxidation stage directly without its isolation. Also, invention proposes additive salt of trifluoroacetic acid of compound of the formula (3) and a method for its preparing by treatment of compound of the formula (3) with trifluoroacetic acid. Invention provides increasing yield and improving purity of the end product.

EFFECT: improved preparing method.

11 cl, 6 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with infecting macrophages and cells of macrophagous cell lines with pathogenic microorganisms, their treatment with medicinal remedies followed by gamma-irradiation, immunization of disease-resistant and disease-sensitive animal lines and infecting vaccinated animals with alive pathogenic microorganisms that leads to improved immunity to pathogenic microorganisms.

EFFECT: higher efficiency.

4 cl, 1 dwg, 3 ex

FIELD: medicine, gynecology.

SUBSTANCE: one should perform laparoscopy, drain purulent foci, remove destructive tissues and wash abdominal cavity with great amount of "Baliz-2" introduced into abdominal cavity by fractional portions per 1-1.5 l at exposure up to 3 min either once or up to three times. The method provides complex impact as antibacterial, antioxidant and immunocorrecting actions of the preparation in area of lesion and, thus, quick interruption of acute stage by preventing the development of adhesions and saving reproductive function in this category of patients.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: biotechnology, microbiology, medicine, veterinary science.

SUBSTANCE: for preparing vaccine toxigenic strains of S. dysenteriae R-forms are grown, cells are subjected for lysis by treatment with chloroform, mixture is centrifuged and prepared supernatant is treated with saturated monobasic carboxylic acid or their derivatives and pH value is brought about to 3.0-5.0. Mixture if centrifuged and precipitate containing corpuscular antigens and shigellosis exotoxin are obtained. Precipitate is dissolved in buffer and pH value is brought about to 7.5-9.0. Then formalin is added in the amount 0.4-0.8% of the solution volume, or benzoic acid or benzoic acid salts are added in the amount 0.07-4.0% of the solution volume, or a mixture consisting of formalin and benzoic acid or benzoic acid salt solutions in the amount 0.10.3% and 0.03-2.5% of the solution volume, respectively. The solution is kept at temperature 30-60°C for 2 h - 60 days to provide the conversion of exotoxin to anatoxin and vaccine is prepared. Another variant of the claimed invention involves additional treatment with formalin or benzoic acid or benzoic acid salts to provide conversion of exotoxin to anatoxin, vaccine is prepared followed by its bagging and corking. For preparing immunoglobulin preparation animals are immunized with vaccine prepared by abovementioned methods followed by taking off blood, milk and/or colostrums, and/or blood, immunoglobulin fraction is prepared, sterilized, bagged and corked. This preparation is a component of the immunobiological preparation. The immunobiological preparation comprises the immunoglobulin preparation and at least one component taken among the following row: human and/or animal immunoglobulin preparations, lactoferrin, enzymes, inhibitors of proteolytic enzymes, human and/or animal normoflora preparations, yeast, vitamins, vitamin-like substances, human and/or animal proteins of acute phase, human and/or animal cytokines, higher plants components, lower plants components, components of natural origin products, apiculture products, enterosorbents, antibiotics, antibacterial chemopreparations, sulfanilamide drugs, antibacterial, anti-tuberculosis, antiviral preparations, antifungal antibiotics, synthetic antifungal preparations, stimulators of metabolic processes, antioxidants, mineral supplements, carbohydrates, lipids, replaceable and/or essential amino acids, organic acids, alkaloids, glycosides, taste supplements, aromatic supplements, base for suppositories, base for ointment formulations, technological additives for tableting, or their mixture. Invention provides preparing preparations eliciting antigenic activity with respect to broad species of pathogenic and opportunistic gram-negative microorganisms of intestine group and their exotoxins and therefore eliciting with prophylactic and curative effect with respect to diseases causing with these microorganisms.

EFFECT: improved preparing method, valuable properties of vaccine.

13 cl, 112 ex

Antibacterial agent // 2262346

FIELD: biotechnology, microbiology.

SUBSTANCE: invention proposes applying Flavobacterium odoratum culture as an antibacterial agent isolated from drinking mineral water "Ust-Kachkinskaya" from the hole 1/99. Microorganism Flavobacterium odoratum inhibits growth of Staphylococcus aureus, colon bacillus and yeast-like fungi Candida albicans that allows using microorganism Flavobacterium odoratum as an antibacterial agent. Invention can be used as an antibacterial agent.

EFFECT: valuable medicinal properties of agent.

2 ex

FIELD: biotechnology, medicine, antibiotics.

SUBSTANCE: invention proposes to the new compound amycomycin of the molecular formula C65H115NO18 (structural formula is given on the invention claim) that shows an antibacterial activity. Amycomycin, its pharmaceutically acceptable salts and derivatives in all their stereoisomeris and tautomeric forms can be obtained by culturing microorganism Amycolatopsis sp. ST 101170 (DSM 12216) under aerobic conditions on the nutrient medium containing the necessary nutrient components. The end product is isolated and purified and converted if necessary to its pharmacologically acceptable salt, ester, ether and other chemical derivatives and eliciting the same spectrum of antibacterial activity. Amycomycin is a component of the pharmaceutical composition eliciting an antibacterial activity. Amycomycin acts as an antibiotic. Invention provides inhibition of microorganisms with resistance to vancomycin and teicoplanin used in treatment of infections caused by Staphylococcus aureus.

EFFECT: improved preparing method, valuable medicinal properties of amycomycin.

7 cl, 2 tbl, 4 ex

FIELD: medicine, stomatology.

SUBSTANCE: for treating one should apply successively 3%-hydrogen peroxide solution followed by 1%-silver nitrate solution. This provides high antiseptic effect in combination with minimal dental dyeing with solver nitrate solution.

EFFECT: higher efficiency.

6 ex, 1 tbl

FIELD: pharmaceutics.

SUBSTANCE: the innovation deals with manufacturing remedies to prevent wound suppuration based upon polymeric matrix and antimicrobial substance due to mixing components in solution, forming the film to obtain a powder-like medicinal form by providing the safety of antimicrobial activity of medicinal preparation. The obtained remedy is completely biodestructed in the body and requires no repeated operation on its removal after the end of tissue regeneration processes.

EFFECT: higher efficiency of manufacturing.

1 cl, 3 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: the suggested preparation for preventing and treating foot rot in animals includes the product of mustard seeds processing - allyl mustard oil and an emulsifier - an aqueous bischofite solution of natural mineral at the following ratio of components, weight%: allyl mustard oil 0.01-1.0, bischofite 2.0-20.0, water - the rest. The suggested composition is highly efficient and provides improved curative effect after 5-10 foot baths in animals.

EFFECT: higher efficiency.

2 ex

FIELD: veterinary science.

SUBSTANCE: invention relates to methods for preparing chemotherapeutic preparation comprising biologically active iodine. Method for preparing bismuth iodide sulfamide is carried out by addition of bismuth basic nitrate to potassium iodide an aqueous solution and heating the reaction mass in acid medium up to 75-80oC. Then streptocide is added and heating is continued up to 100-105oC, kept at this temperature up to the melt formation followed by cooling and grinding. Method provides preparing the end product with the content of elemental iodine 10.8-11.0% by the wasteless technology for a single stage.

EFFECT: improved preparing method.

3 ex

FIELD: medicine; medical engineering.

SUBSTANCE: means is composed of spherical and close-to-spherical 500-3000 mcm large microgranules. Microgranule matrix has at least one cross-linked polymer and fillers. The cross-linked polymer is taken as sodium alginate, or gelatin, or pectin, or carraginan, or agar-agar, or sodium salt of carboxycellulose, or copolymer of acrylic acid and butylacrylate, or their mixtures. The fillers are hyperosmolar, antiseptic, anesthetic and, when required, antioxidant compounds. Method involves placing microgranules into pyoinflammatory lesion focus through postoperative or fresh wound. Wound cavity space is filled with microgranules to not more than one-half of its volume. Then the wound is drained and covered with antiseptic bandage. The granules and bandage are changed once a day during 2-3 days.

EFFECT: enhanced effectiveness of treatment; prolonged drug concentration support in wound.

6 cl,1 tbl

The invention relates to medicine and can be used for the treatment of angina

The invention relates to medicine and can be used in surgery, dentistry, gynecology, traumatology, sports medicine, at home, with operating procedures and the damage associated with bleeding, especially in the presence of infection
The invention relates to medicine, in particular to the gynecologist, and for the treatment of chronic adnexitis

The invention relates to medicine, specifically to the means which have an antimicrobial effect on local purulent-inflammatory processes of the soft tissues and used in surgery, dermatology, obstetrics, gynecology, otolaryngology

FIELD: pharmacology.

SUBSTANCE: according to the present invention pharmacological composition is in form of quick soluble granules, containing particles of at least two different carrier materials with surface being at least partially coated with at least one layer, comprising 50-120 wt.pts, preferably, 60-100 wt.pts of at least one active ingredient based on 100 wt.pts of carrier material. Active ingredient is preferably insoluble or low soluble substance such as amino acids or antioxidants. The first carrier material comprises about 50-80 wt.% of total carrier material and has bulk density of 58-100 g/ml, preferably of 63-90 g/100 ml. The second carrier material has bulk density of 30-55 g/100 ml, preferably of 33-50 g/100 ml. Granulated composition has high solubility, high content of active ingredient and little amount of excipients. Further composition is quickly suspended in little amount of water, doesn't form agglomerates for a long time, ant has acceptable taste.

EFFECT: pharmacological composition in form of quick soluble granules with improved quality.

22 cl, 4 tbl, 5 ex